Biogen, a major pharmaceutical company, is undergoing significant changes. They’re moving to a new headquarters near Boston and expanding beyond their well-known multiple sclerosis treatments. Guy Hadari, the company’s senior vice president and global chief information officer, is leading this tech-driven transformation. His goal is to use technology to improve business outcomes, not just chase every new tech trend. Biogen already has successful drugs like Spinraza for rare diseases and Leqembi for Alzheimer’s, along with partnerships with other biopharma companies. Despite a slow year in 2025, they’re building a strong pipeline for the future. Hadari believes that the role of a CIO has evolved from being behind the scenes to being crucial for a company’s success. He’s integrating technology into all aspects of Biogen’s business, from patient services to AI models that save costs. Hadari explains that Biogen is transitioning from focusing on one area to having a diverse range of products. This change requires updating their processes and systems. They’ve already updated their research and development systems and are working on their patient services platform. Hadari is cautious about AI, emphasizing the need for clear outcomes linked to revenue or cost. He breaks AI into three layers: basic tools, tactical projects, and strategic bets. For Alzheimer’s research, Hadari’s role is to integrate data from different departments to help in drug development. He believes that their IT team is crucial for Biogen’s success in the coming years.